BackPainReform Overview

PainReform Current Cash

Latest current cash for PRFX: $3.1M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$3.13M
↓ 26.66% YoYΔ $-1.14M vs prior year quarter

Peer average

Loading

PainReform Current Cash History

Loading

PainReform vs. peers: Current Cash Comparison

Loading

PainReform Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

PainReform (PRFX) FAQ

PainReform (PRFX) currently reports a current cash of $3.1M as of December 2025. That compares with $4.3M in the prior-year period — down 26.7% year over year. Use the charts on this page to explore PainReform's current cash history and peer comparisons.

PainReform's current cash decreased from $4.3M to $3.1M — a 26.7% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PainReform reported $3.1M in current cash as of December 2025. That compares with $4.3M in the prior-year period — down 26.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $3.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PainReform, and consider following PRFX for alerts when major investors trade the stock.

PainReform is classified in the Healthcare sector. On current cash, it currently shows $3.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRFX with unrelated industries.